Sten Nilsson

Publications
Public outreach and news

Articles

Article: EUROPEAN JOURNAL OF CANCER. 2023;181:198-207

A randomised, double-blind, dose-finding, phase II multicentre study of ODX in the treatment of patients with castration-resistant prostate cancer and skeletal metastases.

Thellenberg-Karlsson C; Vjaters E; Kase M; Tammela T; Ojamaa K; Norming U; Nyman C; Andersson S-O; Hublarovs O; Marquez-Holmberg M; Castellanos E; Ullen A; Holmberg A; Nilsson S
Article: TRANSLATIONAL ONCOLOGY. 2022;26:101543

Ra-223 induces clustered DNA damage and inhibits cell survival in several prostate cancer cell lines.

Abramenkovs A; Hariri M; Spiegelberg D; Nilsson S; Stenerlöw B
Article: ACTA ONCOLOGICA. 2022;61(10):1179-1185

High levels of health-related quality of life five years after curative treatment of prostate cancer with HDR-brachytherapy and external beam radiation.

Hjälm-Eriksson M; Ullén A; Nilsson S; Johansson H; Nilsson J; Castellanos E; Brandberg Y
Article: ACTA ONCOLOGICA. 2021;60(10):1301-1307

High rate of local control and cure at 10 years after treatment of prostate cancer with external beam radiotherapy and high-dose-rate brachytherapy: a single centre experience.

Hjälm-Eriksson M; Nilsson S; Brandberg Y; Johansson H; Lennernäs B; Lundell G; Castellanos E; Ullén A
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2021;48(10):3325-3334

Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223.

van der Doelen MJ; Stockhaus A; Ma Y; Mehra N; Yachnin J; Gerritsen WR; Nilsson S; van Oort IM; Ullén A
Article: CLINICAL GENITOURINARY CANCER. 2019;17(5):348-355.e5

Disease Characteristics and Completion of Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Radium-223 in an International Early Access Program.

Saad F; Gillessen S; Heinrich D; Keizman D; O'Sullivan JM; Nilsson S; Miller K; Wirth M; Reeves J; Seger M; Carles J; Heidenreich A
Article: BMC CANCER. 2019;19(1):12

Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program.

Heidenreich A; Gillessen S; Heinrich D; Keizman D; O'Sullivan JM; Carles J; Wirth M; Miller K; Reeves J; Seger M; Nilsson S; Saad F
Article: EUROPEAN UROLOGY. 2018;73(3):427-435

Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial.

Parker CC; Coleman RE; Sartor O; Vogelzang NJ; Bottomley D; Heinrich D; Helle SI; O'Sullivan JM; Fosså SD; Chodacki A; Wiechno P; Logue J; Seke M; Widmark A; Johannessen DC; Hoskin P; James ND; Solberg A; Syndikus I; Kliment J; Wedel S; Boehmer S; Dall'Oglio M; Franzén L; Bruland ØS; Petrenciuc O; Staudacher K; Li R; Nilsson S
Article: ANTICANCER RESEARCH. 2018;38(3):1531-1537

Synthesis and Binding of a Novel PSMA-specific Conjugate.

Holmberg AR; Marquez M; Lennartsson L; Meurling L; Nilsson S
Article: MOLECULAR AND CLINICAL ONCOLOGY. 2018;8(1):141-146

Effect on prostate volume following neoadjuvant treatment with an androgen receptor inhibitor monotherapy versus castration plus an androgen receptor inhibitor in prostate cancer patients intended for curative radiation therapy: A randomised study.

Majumder K; Brandberg Y; Johansson H; Castellanos E; Ullén A; Lennernäs B; Nilsson S
Article: CLINICAL GENITOURINARY CANCER. 2017;:S1558-7673(17)30275-6-E231

The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer.

Heinrich D; Bektic J; Bergman AM; Caffo O; Cathomas R; Chi KN; Daugaard G; Keizman D; Kindblom J; Kramer G; Olmos D; Omlin A; Sridhar SS; Tucci M; van Oort I; Nilsson S
Article: ANNALS OF ONCOLOGY. 2017;28(5):1090-1097

An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223.

Sartor O; Coleman RE; Nilsson S; Heinrich D; Helle SI; O'Sullivan JM; Vogelzang NJ; Bruland Ø; Kobina S; Wilhelm S; Xu L; Shan M; Kattan MW; Parker C
Article: CLINICAL GENITOURINARY CANCER. 2017;15(1):42-52.e8

Hematologic Safety of Radium-223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial.

Vogelzang NJ; Coleman RE; Michalski JM; Nilsson S; O'Sullivan JM; Parker C; Widmark A; Thuresson M; Xu L; Germino J; Sartor O
Article: ACTA ONCOLOGICA. 2017;56(1):21-26

Comorbidity as a predictor of overall survival in prostate cancer patients treated with external beam radiotherapy combined with HDR brachytherapy boosts.

Hjälm-Eriksson M; Ullén A; Johansson H; Levitt S; Nilsson S; Kälkner K-M
Article: EUROPEAN JOURNAL OF CANCER. 2017;71:1-6

Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial.

Parker C; Zhan L; Cislo P; Reuning-Scherer J; Vogelzang NJ; Nilsson S; Sartor O; O'Sullivan JM; Coleman RE
Article: ANTICANCER RESEARCH. 2016;36(12):6499-6504

Bone-targeted Novel Cytotoxic Polybisphosphonate Conjugate in Castration-resistant Prostate Cancer: A Multicenter Phase 1 Study.

Thellenberg-Karlsson C; Nyman C; Nilsson S; Blom R; Márquez M; Castellanos E; Holmberg AR
Article: EUROPEAN UROLOGY. 2016;70(5):875-883

Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial.

Parker C; Finkelstein SE; Michalski JM; O'Sullivan JM; Bruland Ø; Vogelzang NJ; Coleman RE; Nilsson S; Sartor O; Li R; Seger MA; Bottomley D
Article: LANCET ONCOLOGY. 2016;17(9):1306-1316

Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.

Saad F; Carles J; Gillessen S; Heidenreich A; Heinrich D; Gratt J; Lévy J; Miller K; Nilsson S; Petrenciuc O; Tucci M; Wirth M; Federhofer J; O'Sullivan JM; Radium-223 International Early Access Program Inve
Article: EUROPEAN JOURNAL OF CANCER. 2016;65:43-51

Higher sexual interest with androgen receptor inhibitor monotherapy than with castration plus an androgen receptor inhibitor in prostate cancer patients treated with curative radiotherapy, but otherwise small health-related quality of life differences: A randomised prospective 18-month follow-up study.

Majumder K; Nilsson S; Johansson H; Ullén A; Lennernäs B; Bergenmar M; Brandberg Y
Article: MEDICINE. 2016;95(31):e4308

Progression-free and overall survival in metastatic castration-resistant prostate cancer treated with abiraterone acetate can be predicted with serial C11-acetate PET/CT.

Farnebo J; Wadelius A; Sandström P; Nilsson S; Jacobsson H; Blomqvist L; Ullén A
Article: PROSTATE. 2016;76(10):905-916

Chemotherapy following radium-223 dichloride treatment in ALSYMPCA.

Sartor O; Hoskin P; Coleman RE; Nilsson S; Vogelzang NJ; Petrenciuc O; Staudacher K; Thuresson M; Parker C
Article: ANNALS OF ONCOLOGY. 2016;27(5):868-874

Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study.

Nilsson S; Cislo P; Sartor O; Vogelzang NJ; Coleman RE; O'Sullivan JM; Reuning-Scherer J; Shan M; Zhan L; Parker C
Article: PLOS ONE. 2016;11(1):e0145545

Improving the Prediction of Prostate Cancer Overall Survival by Supplementing Readily Available Clinical Data with Gene Expression Levels of IGFBP3 and F3 in Formalin-Fixed Paraffin Embedded Core Needle Biopsy Material.

Peng Z; Andersson K; Lindholm J; Dethlefsen O; Pramana S; Pawitan Y; Nistér M; Nilsson S; Li C
Article: SPRINGERPLUS. 2016;5(1):1861

Identification of mutations, gene expression changes and fusion transcripts by whole transcriptome RNAseq in docetaxel resistant prostate cancer cells.

Ma Y; Miao Y; Peng Z; Sandgren J; De Ståhl TD; Huss M; Lennartsson L; Liu Y; Nistér M; Nilsson S; Li C
Article: ONCOTARGET. 2015;6(35):37066-37082

Sorafenib-induced defective autophagy promotes cell death by necroptosis.

Kharaziha P; Chioureas D; Baltatzis G; Fonseca P; Rodriguez P; Gogvadze V; Lennartsson L; Björklund A-C; Zhivotovsky B; Grandér D; Egevad L; Nilsson S; Panaretakis T
Article: ONCOTARGET. 2015;6(25):21740-21754

Molecular profiling of prostate cancer derived exosomes may reveal a predictive signature for response to docetaxel.

Kharaziha P; Chioureas D; Rutishauser D; Baltatzis G; Lennartsson L; Fonseca P; Azimi A; Hultenby K; Zubarev R; Ullén A; Yachnin J; Nilsson S; Panaretakis T
Article: ANNALS OF ONCOLOGY. 2015;26(8):1589-1604

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.

Gillessen S; Omlin A; Attard G; de Bono JS; Efstathiou E; Fizazi K; Halabi S; Nelson PS; Sartor O; Smith MR; Soule HR; Akaza H; Beer TM; Beltran H; Chinnaiyan AM; Daugaard G; Davis ID; De Santis M; Drake CG; Eeles RA; Fanti S; Gleave ME; Heidenreich A; Hussain M; James ND; Lecouvet FE; Logothetis CJ; Mastris K; Nilsson S; Oh WK; Olmos D; Padhani AR; Parker C; Rubin MA; Schalken JA; Scher HI; Sella A; Shore ND; Small EJ; Sternberg CN; Suzuki H; Sweeney CJ; Tannock IF; Tombal B
Article: MOLECULAR AND CELLULAR BIOCHEMISTRY. 2015;406(1-2):111-119

Baicalein inhibits prostate cancer cell growth and metastasis via the caveolin-1/AKT/mTOR pathway.

Guo Z; Hu X; Xing Z; Xing R; Lv R; Cheng X; Su J; Zhou Z; Xu Z; Nilsson S; Liu Z
Article: ACTA ONCOLOGICA. 2015;54(6):875-881

Radical prostatectomy versus high-dose irradiation in localized/locally advanced prostate cancer: A Swedish multicenter randomized trial with patient-reported outcomes.

Lennernäs B; Majumder K; Damber J-E; Albertsson P; Holmberg E; Brandberg Y; Isacsson U; Ljung G; Damm O; Nilsson S
Article: ACTA ONCOLOGICA. 2015;54(2):275-279

A template for writing radiotherapy protocols.

Nilsson P; Ceberg C; Kjellén E; Gagliardi G; Blomgren K; Nilsson S; Johansson M; Glimelius B
Article: PLOS ONE. 2015;10(5):e0124292

Somatostatin Derivate (smsDX) Attenuates the TAM-Stimulated Proliferation, Migration and Invasion of Prostate Cancer via NF-κB Regulation.

Guo Z; Xing Z; Cheng X; Fang Z; Jiang C; Su J; Zhou Z; Xu Z; Holmberg A; Nilsson S; Liu Z
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2015;46(1):381-388

Long-term health-related quality of life after curative treatment for prostate cancer: a regional cross-sectional comparison of two standard treatment modalities.

Hjälm-Eriksson M; Lennernäs B; Ullén A; Johansson H; Hugosson J; Nilsson S; Brandberg Y
Article: LANCET ONCOLOGY. 2014;15(12):1397-1406

Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial.

Hoskin P; Sartor O; O'Sullivan JM; Johannessen DC; Helle SI; Logue J; Bottomley D; Nilsson S; Vogelzang NJ; Fang F; Wahba M; Aksnes A-K; Parker C
Article: LANCET ONCOLOGY. 2014;15(7):738-746

Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial.

Sartor O; Coleman R; Nilsson S; Heinrich D; Helle SI; O'Sullivan JM; Fosså SD; Chodacki A; Wiechno P; Logue J; Widmark A; Johannessen DC; Hoskin P; James ND; Solberg A; Syndikus I; Vogelzang NJ; O'Bryan-Tear CG; Shan M; Bruland ØS; Parker C
Article: CLINICAL GENITOURINARY CANCER. 2014;12(3):e71-e82

Less satisfaction with information in patients with prostate cancer treated with surgery and salvage radiotherapy compared with patients treated with curative radiotherapy alone, despite similar health-related quality of life.

Majumder K; Brandberg Y; Johansson H; Nilsson S; Bergenmar M
Article: PROSTATE CANCER AND PROSTATIC DISEASES. 2014;17(1):81-90

An expression signature at diagnosis to estimate prostate cancer patients' overall survival.

Peng Z; Skoog L; Hellborg H; Jonstam G; Wingmo I-L; Hjälm-Eriksson M; Harmenberg U; Cedermark GC; Andersson K; Ahrlund-Richter L; Pramana S; Pawitan Y; Nistér M; Nilsson S; Li C
Article: CANCER GENOMICS & PROTEOMICS. 2014;11(1):39-49

Proteomic analysis of soft tissue tumor implants treated with a novel polybisphosphonate.

Alaiya A; Fox J; Bobis S; Matic G; Shinwari Z; Barhoush E; Márquez M; Nilsson S; Holmberg AR
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2013;369(3):213-223

Alpha emitter radium-223 and survival in metastatic prostate cancer.

Parker C; Nilsson S; Heinrich D; Helle SI; O'Sullivan JM; Fosså SD; Chodacki A; Wiechno P; Logue J; Seke M; Widmark A; Johannessen DC; Hoskin P; Bottomley D; James ND; Solberg A; Syndikus I; Kliment J; Wedel S; Boehmer S; Dall'Oglio M; Franzén L; Coleman R; Vogelzang NJ; O'Bryan-Tear CG; Staudacher K; Garcia-Vargas J; Shan M; Bruland ØS; Sartor O; ALSYMPCA Investigators
Article: ANTI-CANCER DRUGS. 2013;24(6):648-652

Clinical activity of sorafenib in a previously treated advanced urothelial cancer patient.

Shah C-H; Viktorsson K; Sherif A; Kanter L; Grybäck P; Lewensohn R; Sandström P; Nilsson S; Ullén A
Article: CLINICAL GENITOURINARY CANCER. 2013;11(1):20-26

Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases.

Nilsson S; Franzén L; Parker C; Tyrrell C; Blom R; Tennvall J; Lennernäs B; Petersson U; Johannessen DC; Sokal M; Pigott K; O'Bryan-Tear CG; Thuresson M; Bolstad B; Bruland ØS
Article: LANCET ONCOLOGY. 2013;14(2):117-124

2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial.

Kellokumpu-Lehtinen P-L; Harmenberg U; Joensuu T; McDermott R; Hervonen P; Ginman C; Luukkaa M; Nyandoto P; Hemminki A; Nilsson S; McCaffrey J; Asola R; Turpeenniemi-Hujanen T; Laestadius F; Tasmuth T; Sandberg K; Keane M; Lehtinen I; Luukkaala T; Joensuu H; PROSTY study group
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2013;42(1):109-117

Early salvage radiation therapy combined with short-term hormonal therapy in recurrent prostate cancer after radical prostatectomy: single-institution 4-year data on outcome, toxicity, health-related quality of life and co-morbidities from 184 consecutive patients treated with 70 Gy.

Cortés-González JR; Castellanos E; Sandberg K; Eriksson M-H; Wiklund P; Carlsson S; Cohn-Cedermark G; Harmenberg U; Gustafsson O; Levitt SH; Lennernäs B; Brandberg Y; Márquez M; Kälkner K-M; Nilsson S
Article: EUROPEAN UROLOGY. 2012;61(6):1229-1238

Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer.

Rosenblatt R; Sherif A; Rintala E; Wahlqvist R; Ullén A; Nilsson S; Malmström P-U; Nordic Urothelial Cancer Group
Article: CELL DEATH & DISEASE. 2012;3(1):e262

Targeting of distinct signaling cascades and cancer-associated fibroblasts define the efficacy of Sorafenib against prostate cancer cells.

Kharaziha P; Rodriguez P; Li Q; Rundqvist H; Björklund A-C; Augsten M; Ullén A; Egevad L; Wiklund P; Nilsson S; Kroemer G; Grander D; Panaretakis T
Article: ANTICANCER RESEARCH. 2011;31(12):4141-4145

Treatment of bone metastasis in prostate cancer: efficacy of a novel polybisphosphonate.

Daubine F; LE Bot R; Márquez M; Nilsson S; Schröder T; Holmberg AR
Article: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2011;81(4):997-1004

Use of the Charlson combined comorbidity index to predict postradiotherapy quality of life for prostate cancer patients.

Wahlgren T; Levitt S; Kowalski J; Nilsson S; Brandberg Y
Article: RAPID COMMUNICATIONS IN MASS SPECTROMETRY. 2011;25(17):2453-2458

Application of accelerator mass spectrometry to macromolecules: preclinical pharmacokinetic studies on a polybisphosphonate.

Salehpour M; Håkansson K; Höglund U; Grahn-Westin A; Nilsson S; Márquez M; Possnert G; Holmberg AR
Article: ACTA ONCOLOGICA. 2011;50 Suppl 1:111-115

Hypofractionation for radiotherapy of prostate cancer using a low alfa/beta ratio--possible reasons for concerns? An example of five dimensional radiotherapy.

Lennernäs B; Nilsson S; Levitt S
Article: ACTA ONCOLOGICA. 2011;50 Suppl 1:104-110

Four and five dimensional radiotherapy with reference to prostate cancer--definitions, state of the art and further directions--an overview.

Lennernäs B; Castellanos E; Nilsson S; Levitt S
Article: ACTA ONCOLOGICA. 2011;50 Suppl 1:98-103

Curative radiation therapy in prostate cancer.

Harmenberg U; Hamdy FC; Widmark A; Lennernäs B; Nilsson S
Article: JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH. 2010;29(1):162

XAF1 expression and regulatory effects of somatostatin on XAF1 in prostate cancer cells.

Xing Z; Zhou Z; Yu R; Li S; Li C; Nilsson S; Liu Z
Article: JOURNAL OF BIOMEDICAL OPTICS. 2010;15(5):058003

System for interstitial photodynamic therapy with online dosimetry: first clinical experiences of prostate cancer.

Swartling J; Axelsson J; Ahlgren G; Kälkner KM; Nilsson S; Svanberg S; Svanberg K; Andersson-Engels S
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2010;37(3):563-567

Development of a novel poly bisphosphonate conjugate for treatment of skeletal metastasis and osteoporosis.

Holmberg AR; Lerner UH; Alayia AA; Al-Mohanna M; Adra C; Marquez M; Meurling L; Nilsson S
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2010;37(1):15-20

Sorafenib induces apoptosis and autophagy in prostate cancer cells in vitro.

Ullén A; Farnebo M; Thyrell L; Mahmoudi S; Kharaziha P; Lennartsson L; Grandér D; Panaretakis T; Nilsson S
Article: ONCOLOGY REPORTS. 2009;22(6):1451-1458

Comparison of protein expression in two prostate cancer cell-lines, LNCaP and DU145, after treatment with somatostatin.

Liu Z; Marquez M; Nilsson S; Holmberg AR
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2009;35(2):281-285

Polymer-conjugated guanidine is a potentially useful anti-tumor agent.

Meurling L; Márquez M; Nilsson S; Holmberg AR
Article: SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY. 2009;43(2):98-103

Zoledronic acid induces caspase-dependent apoptosis in renal cancer cell lines.

Ullen A; Schwarz S; Lennartsson L; Kalkner K-M; Sandstrom P; Costa F; Lennernas B; Linder S; Nilsson S
Article: EXPERIMENTAL CELL RESEARCH. 2008;314(14):2529-2543

Identification and expression analysis of an N-terminally truncated isoform of human PDGF-C.

Zhao J; Liu Z; Liu T; Nilsson S; Nistér M
Article: ONCOLOGY REPORTS. 2008;20(1):151-154

Incubation with somatostatin, 5-aza decitabine and trichostatin up-regulates somatostatin receptor expression in prostate cancer cells.

Liu Z; Marquez M; Nilsson S; Holmberg AR
Article: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2008;71(1):36-40

Is the use of a surrogate urethra an option in prostate high-dose-rate brachytherapy?

Nilsson J; Kälkner KM; Berg L; Levitt S; Holmberg C; Nilsson S; Lundell M
Article: SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, SUPPLEMENT. 2008;(218):89-92

Chemotherapy-induced bladder cancer.

Nilsson S; Ullén A
Article: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2007;69(3):662-670

Promising long-term health-related quality of life after high-dose-rate brachytherapy boost for localized prostate cancer.

Wahlgren T; Nilsson S; Lennernäs B; Brandberg Y
Article: ONCOLOGY REPORTS. 2007;18(5):1299-1303

Calculated and simulated effects of heterogeneous dose distributions in radiotherapy using the dose volume inhomogeneity corrected biological equivalent dose formula with special reference to prostate cancer.

Lennernäs B; Albertsson P; Edgren M; Nilsson S
Article: LANCET ONCOLOGY. 2007;8(7):587-594

Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.

Nilsson S; Franzén L; Parker C; Tyrrell C; Blom R; Tennvall J; Lennernäs B; Petersson U; Johannessen DC; Sokal M; Pigott K; Yachnin J; Garkavij M; Strang P; Harmenberg J; Bolstad B; Bruland OS
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2007;30(5):1173-1179

Somatostatin effects on the proteome of the LNCaP cell-line.

Liu Z; Bengtsson S; Krogh M; Marquez M; Nilsson S; James P; Aliaya A; Holmberg AR
Article: ACTA ONCOLOGICA. 2007;46(7):909-917

Clinical outcome in patients with prostate cancer treated with external beam radiotherapy and high dose-rate iridium 192 brachytherapy boost: a 6-year follow-up.

Kälkner KM; Wahlgren T; Ryberg M; Cohn-Cedermark G; Castellanos E; Zimmerman R; Nilsson J; Lundell M; Fowler J; Levitt S; Hellström M; Nilsson S
Article: BRACHYTHERAPY. 2007;6(1):49-52

Dosimetry of anal radiation in high-dose-rate brachytherapy for prostate cancer.

Kälkner KM; Bengtsson E; Eriksson S; Holmberg C; Nilsson S; Levitt S; Lundell M
Article: RADIOTHERAPY AND ONCOLOGY. 2006;81(3):291-293

Prostate displacement kit: reducing the radiation dose to the rectum.

Kälkner KM; Nilsson J; Lundell M; Levitt S; Nilsson S
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2006;29(6):1517-1524

High dose-rate brachytherapy of prostate cancer utilising Iridium-192 after-loading technique: technical and methodological aspects.

Edgren M; Ekelund AM; Albertsson P; Lundberg LM; Ullen A; Levitt S; Nilsson S; Lennernäs B
Article: RADIOTHERAPY AND ONCOLOGY. 2006;81(2):179-183

Prostate volume determination: differential volume measurements comparing CT and TRUS.

Kälkner KM; Kubicek G; Nilsson J; Lundell M; Levitt S; Nilsson S
Article: INTERNATIONAL JOURNAL OF CANCER. 2006;119(4):847-853

Prostasome-derived proteins capable of eliciting an immune response in prostate cancer patients.

Ronquist KG; Carlsson L; Ronquist G; Nilsson S; Larsson A
Article: BRITISH JOURNAL OF CANCER. 2006;94(11):1658-1662

Nucleostemin mRNA is expressed in both normal and malignant renal tissues.

Fan Y; Liu Z; Zhao S; Lou F; Nilsson S; Ekman P; Xu D; Fang X
Article: UPSALA JOURNAL OF MEDICAL SCIENCES. 2006;111(3):293-301

Mode of growth determines differential expression of prostasomes in cultures of prostate cancer cell lines and opens for studies of prostasome gene expression.

Carlsson L; Lennartsson L; Ronquist G; Larsson A; Nilson S; Nilsson O
Article: CANCER GENOMICS & PROTEOMICS. 2005;2(6):347-352

Proteomic Analysis of a Human Prostate Cancer Cell Line after Incubation with a Novel Somatostatin14 Derivative.

Liu Z; Mrquez M; Nilsson S; Holmberg AR; Alaiya A
Article: RADIOTHERAPY AND ONCOLOGY. 2005;77(1):88-95

Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma.

Wersäll PJ; Blomgren H; Lax I; Kälkner K-M; Linder C; Lundell G; Nilsson B; Nilsson S; Näslund I; Pisa P; Svedman C
Article: CANCER NURSING. 2005;28(4):256-262

Testicular cancer and testicular self-examination: knowledge and attitudes of adolescent Swedish men.

Rudberg L; Nilsson S; Wikblad K; Carlsson M
Article: CLINICAL CANCER RESEARCH. 2005;11(12):4451-4459

First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases.

Nilsson S; Larsen RH; Fosså SD; Balteskard L; Borch KW; Westlin J-E; Salberg G; Bruland OS
Article: EUROPEAN JOURNAL OF CANCER. 2005;41(7):990-997

Intention to test for prostate cancer.

Berglund G; Nilsson S; Nordin K
Article: JOURNAL OF PAIN AND SYMPTOM MANAGEMENT. 2005;29(4):352-357

Palliation of bone pain in prostate cancer using chemotherapy and strontium-89. A randomized phase II study.

Nilsson S; Strang P; Ginman C; Zimmermann R; Edgren M; Nordström B; Ryberg M; Kälkner K-M; Westlin J-E
Article: JOURNAL OF SCHOOL NURSING. 2005;21(1):17-22

Barriers identified by Swedish school nurses in giving information about testicular cancer and testicular self-examination to adolescent males.

Rudberg L; Nilsson S; Wikblad K; Carlsson M
Article: ACTA ONCOLOGICA. 2005;44(6):644-650

Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid.

Ullén A; Lennartsson L; Harmenberg U; Hjelm-Eriksson M; Kälkner KM; Lennernäs B; Nilsson S
Article: ACTA ONCOLOGICA. 2005;44(6):633-643

Combined curative radiotherapy including HDR brachytherapy and androgen deprivation in localized prostate cancer: a prospective assessment of acute and late treatment toxicity.

Wahlgren T; Nilsson S; Ryberg M; Lennernäs B; Brandberg Y
Article: ACTA ONCOLOGICA. 2005;44(5):490-495

Prostate cancer cell lines lack amplification: overexpression of HER2.

Ullén A; Lennartsson L; Harmenberg U; Lennernäs B; Majumder K; Holmberg AR; Nilsson S; Elmberger GP
Article: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2004;60(1):51-59

Health-related quality of life in men after treatment of localized prostate cancer with external beam radiotherapy combined with (192)ir brachytherapy: a prospective study of 93 cases using the EORTC questionnaires QLQ-C30 and QLQ-PR25.

Wahlgren T; Brandberg Y; Häggarth L; Hellström M; Nilsson S
Article: BRITISH JOURNAL OF CANCER. 2004;91(4):688-694

A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer.

Pavlenko M; Roos A-K; Lundqvist A; Palmborg A; Miller AM; Ozenci V; Bergman B; Egevad L; Hellström M; Kiessling R; Masucci G; Wersäll P; Nilsson S; Pisa P
Article: ANTICANCER RESEARCH. 2004;24(3a):1347-1351

Charge-dependent targeting: results in six tumor cell lines.

Márquez M; Nilsson S; Lennartsson L; Liu Z; Tammela T; Raitanen M; Holmberg AR
Article: EUROPEAN UROLOGY. 2004;45(3):297-303

Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies.

Sherif A; Holmberg L; Rintala E; Mestad O; Nilsson J; Nilsson S; Malmström P-U; Nordic Urothelial Cancer Group
Article: CANCER NURSING. 2002;25(3):187-195

Self-perceived physical, psychologic, and general symptoms in survivors of testicular cancer 3 to 13 years after treatment.

Rudberg L; Carlsson M; Nilsson S; Wikblad K
Article: ANTICANCER RESEARCH. 2002;22(2A):741-744

Development of dextran derivatives with cytotoxic effects in human urinary bladder cancer cell lines.

Marquez M; Du J; Edgren M; Nilsson S; Lennartsson L; Hiltunen J; Westlin J-E; Tammela T; Raitanen M; Laato M; Jönsson G; Holmberg AR
Article: SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY. 2002;36(6):419-425

Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer -- Nordic cystectomy trial 2.

Sherif A; Rintala E; Mestad O; Nilsson J; Holmberg L; Nilsson S; Malmström P-U; Nordic Urothelial Cancer Group
Article: APPLIED RADIATION AND ISOTOPES. 2001;55(2):181-187

Technetium-99m labelling of glycosylated somatostatin-14.

Du J; Hiltunen J; Marquez M; Nilsson S; Holmberg AR
Article: UROLOGICAL RESEARCH. 2001;29(3):216-220

Radioimmunoscintigraphy using an anti-prostate monoclonal antibody (E4): a dosimetric evaluation.

Rydh A; Riklund Ahlström K; Widmark A; Johansson L; Nilsson S; Bergh A; Damber JE; Stigbrand T; Hietala SO
Article: ANTICANCER RESEARCH. 2001;21(3C):2231-2235

Postoperative radiotherapy after prostatectomy can be associated with severe side effects.

Edgren M; Lennernäs B; Häggman M; Norlén BJ; Nilsson S
Article: ACTA ONCOLOGICA. 2001;40(2-3):135-154

The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of chemotherapy effects in some major tumour types--summary and conclusions.

Glimelius B; Bergh J; Brandt L; Brorsson B; Gunnars B; Hafström L; Haglund U; Högberg T; Janunger KG; Jönsson PE; Karlsson G; Kimby E; Lamnevik G; Nilsson S; Permert J; Ragnhammar P; Sörenson S; Nygren P
Article: MEDICAL ONCOLOGY. 2001;18(1):59-64

Biodistribution, blood half-life, and receptor binding of a somatostatin-dextran conjugate.

Behe M; Du J; Becker W; Behr T; Angerstein C; Márquez M; Hiltunen J; Nilsson S; Holmberg AR
Article: EUROPEAN UROLOGY. 2000;38(5):584-589

Intravesical administration of EGF- dextran conjugates in patients with superficial bladder cancer.

Bue P; Holmberg AR; Márquez M; Westlin JE; Nilsson S; Malmström PU
Article: EUROPEAN UROLOGY. 2000;38(4):468-474

Growth-inhibitory effect of prostasomes on prostatic cancer cell lines in culture.

Carlsson L; Lennartsson L; Nilsson BO; Nilsson S; Ronquist G
Article: APPLIED RADIATION AND ISOTOPES. 2000;53(3):443-448

Radiolabeling of dextran with rhenium-188.

Du J; Marquez M; Hiltunen J; Nilsson S; Holmberg AR
Article: ANTICANCER RESEARCH. 2000;20(4):2321-2324

Human milk fat globule antigen 1 (HMFG1) expression in prostatic carcinoma and immunotargeting with a radiolabelled monoclonal anti-HMFG1 antibody.

Ljung G; Lennernäs B; Nordgren H; Holmberg A; Westlin JE; Nilsson S; Edgren M
Article: CLINICAL SCIENCE. 1999;97(1):111-115

Elevated activity of semicarbazide-sensitive amine oxidase in blood from patients with skeletal metastases of prostate cancer.

Ekblom J; Grönvall J; Lennernäs B; Nilsson S; Garpenstrand H; Oreland L
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 1999;26(3):277-282

Radionuclide therapy practice and facilities in Europe. EANM Radionuclide Therapy Committee.

Hoefnagel CA; Clarke SE; Fischer M; Chatal JF; Lewington VJ; Nilsson S; Troncone L; Vieira MR
Article: CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS. 1999;14(1):59-64

[111In-DPTA-D-Phe1]-octreotide scintigraphy in the management of patients with advanced renal cell carcinoma.

Edgren M; Westlin JE; Kälkner KM; Sundin A; Nilsson S
Article: UPSALA JOURNAL OF MEDICAL SCIENCES. 1999;104(3):199-206

Expression of prostasome-like granules by the prostate cancer cell lines PC3, Du145 and LnCaP grown in monolayer.

Nilsson BO; Lennartsson L; Carlsson L; Nilsson S; Ronquist G
Article: ACTA ONCOLOGICA. 1999;38(8):1109-1112

Patient positioning using artificial intelligence neural networks, trained magnetic field sensors and magnetic implants.

Lennernäs B; Edgren M; Nilsson S
Article: ACTA ONCOLOGICA. 1999;38(8):1075-1079

Radioimmunotherapy of DU-145 tumours in nude mice--a pilot study with E4, a novel monoclonal antibody against prostate cancer.

Rydh A; Riklund-Ahlström K; Widmark A; Bergh A; Johansson L; Tavelin B; Nilsson S; Stigbrand T; Damber JE; Hietala SO
Article: ACTA ONCOLOGICA. 1999;38(2):203-208

Calculated effects of displacement errors in external beam radiotherapy of prostatic adenocarcinoma.

Lennernäs B; Nilsson S
Article: ANTICANCER RESEARCH. 1999;19(1B):869-873

Serum concentrations of VEGF and b-FGF in renal cell, prostate and urinary bladder carcinomas.

Edgren M; Lennernäs B; Larsson A; Nilsson S
Article: ANTICANCER RESEARCH. 1998;18(3B):1983-1987

Pain figures are unsuitable for determination of palliative radiotherapy portals in patients with hormone refractory prostatic cancer.

Kälkner KM; Westlin JE; Nilsson S; Strang P
Article: INTERNATIONAL JOURNAL OF CANCER. 1998;76(2):189-193

Expression of epidermal growth factor receptor in urinary bladder cancer metastases.

Bue P; Wester K; Sjöström A; Holmberg A; Nilsson S; Carlsson J; Westlin JE; Busch C; Malmström PU
Article: INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE. 1998;1(4):693-702

Conjugate chemistry, iodination and cellular binding of mEGF-dextran-tyrosine: preclinical tests in preparation for clinical trials.

Zhao Q; Blomquist E; Bolander H; Gedda L; Hartvig P; Janson J; Lundqvist H; Mellstedt H; Nilsson S; Nistèr M; Sundin A; Tolmachev V; Westlin J; Carlsson J
Article: STEROIDS. 1998;63(4):228-234

Synthesis and in vitro evaluation of [carbonyl-11C]estramustine and [carbonyl-11C]estramustine phosphate.

Lidström P; Bonasera TA; Marquez-M M; Nilsson S; Bergström M; Långström B
Article: BRITISH JOURNAL OF CANCER. 1998;77(8):1311-1317

Survival in renal cell carcinoma-a randomized evaluation of tamoxifen vs interleukin 2, alpha-interferon (leucocyte) and tamoxifen.

Henriksson R; Nilsson S; Colleen S; Wersäll P; Helsing M; Zimmerman R; Engman K
Article: ANTICANCER RESEARCH. 1998;18(2B):1255-1260

GM-CSF in chemotherapy-induced febrile neutropenia--a double-blind randomized study.

Arnberg H; Letocha H; Nõu F; Westlin JF; Nilsson S
Article: SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY. 1998;32(2):111-115

Value of sextant biopsies in the assessment of local cure following external beam radiotherapy of prostatic adenocarcinoma.

Almroth A; Ljung G; Eklund T; Nordgren H; Kalafatidis D; Ringqvist I; Nilsson S
Article: ANTICANCER RESEARCH. 1998;18(1B):513-516

[111In-DTPA-D-Phe1]-octreotide scintigraphy in patients with hormone-refractory prostatic adenocarcinoma can predict therapy outcome with octreotide treatment: a pilot study.

Kälkner KM; Nilsson S; Westlin JE
Article: CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS. 1997;12(6):395-403

E4, a new monoclonal antibody identifying a human prostatic cell surface antigen.

Nilsson S; Essand M; Logdahl P; Larson A; Nordgren H; Juhlin C
Article: ANTICANCER RESEARCH. 1997;17(6D):4717-4721

The analgesic efficacy of clodronate compared with placebo in patients with painful bone metastases from prostatic cancer.

Strang P; Nilsson S; Brändstedt S; Sehlin J; Borghede G; Varenhorst E; Bandman U; Borck L; Englund G; Selin L
Article: IN VIVO. 1997;11(5):377-381

PET with hydroxytryptophan as tracer in hormone-refractory prostatic adenocarcinoma: evaluation of decarboxylation in vivo.

Kälkner KM; Nilsson S; Bergström M; Lindner KJ; Westerberg G; Långström B; Westlin JE
Article: BRITISH JOURNAL OF HAEMATOLOGY. 1997;98(2):312-314

The eosinophil granule proteins in serum, but not the oxidative metabolism of the blood eosinophils, are increased in cancer.

Trulson A; Nilsson S; Venge P
Article: PROSTATE. 1997;32(2):99-105

Expression of p21 and mutant p53 gene products in residual prostatic tumor cells after radical radiotherapy.

Ljung G; Egevad L; Norberg M; Holmberg L; Nilsson S; Busch C
Article: EUROPEAN JOURNAL OF CANCER. 1997;33(7):1038-1044

Risk-adapted treatment of clinical stage 1 non-seminoma testis cancer.

Klepp O; Dahl O; Flodgren P; Stierner U; Olsson AM; Oldbring J; Nilsson S; Daehlin L; Tørnblom M; Småland R; Starkhammar H; Abramsson L; Wist E; Raabe N; Edekling T; Cavallin-Ståhl E
Article: PROSTATE. 1997;31(3):153-160

Anemia associated with advanced prostatic adenocarcinoma: effects of recombinant human erythropoietin.

Beshara S; Letocha H; Linde T; Wikström B; Sandhagen B; Nilsson S; Danielson BG
Article: PROSTATE. 1997;31(2):91-97

Characterization of residual tumor cells following radical radiation therapy for prostatic adenocarcinoma; immunohistochemical expression of prostate-specific antigen, prostatic acid phosphatase, and cytokeratin 8.

Ljung G; Norberg M; Holmberg L; Busch C; Nilsson S
Article: NUCLEAR MEDICINE AND BIOLOGY. 1997;24(4):319-325

Positron emission tomography (PET) with 11C-5-hydroxytryptophan (5-HTP) in patients with metastatic hormone-refractory prostatic adenocarcinoma.

Kälkner KM; Ginman C; Nilsson S; Bergström M; Antoni G; Ahlström H; Långström B; Westlin JE
Article: CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS. 1997;12(2):89-99

Comparison between transversal SPECT, 3-dimensional rendering and 3-dimensional rendering plus clipping in the diagnosis of somatostatin receptor distribution in malignancies using 111In-DTPA-D-Phe1-octreotide scintigraphy.

Kälkner KM; Nilsson S; Ylä-Jääski J; Westlin JE
Article: ANTICANCER RESEARCH. 1997;17(2B):1303-1309

Biological characteristics of adrenocortical carcinoma: a study of p53, IGF, EGF-r, Ki-67 and PCNA in 17 adrenocortical carcinomas.

Edgren M; Eriksson B; Wilander E; Westlin JE; Nilsson S; Oberg K
Article: INTERNATIONAL JOURNAL OF CANCER. 1997;70(4):383-389

Binding, internalization and degradation of EGF-dextran conjugates in two human bladder-cancer cell lines.

Sjöström A; Bue P; Malmström PU; Nilsson S; Carlsson J
Article: ANTICANCER RESEARCH. 1996;16(6B):3871-3874

Neuroendocrine markers; chromogranin, pancreastatin and serotonin in the management of patients with advanced renal cell carcinoma.

Edgren M; Stridsberg M; Kalknar KM; Nilsson S
Article: CANCER. 1996;78(9):1942-1951

A comparison of proliferation markers and their prognostic value for women with endometrial carcinoma. Ki-67, proliferating cell nuclear antigen, and flow cytometric S-phase fraction.

Nordström B; Strang P; Bergström R; Nilsson S; Tribukait B
Article: PROSTATE. 1996;29(5):303-310

Assessment of proliferation indicators in residual prostatic adenocarcinoma cells after radical external beam radiotherapy.

Ljung G; Egevad L; Norberg M; de la Torre M; Holmberg L; Busch C; Nilsson S
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 1996;43(1):39-43

Retention and processing of the monoclonal anti-prostate E4 antibody after binding to prostatic adenocarcinoma DU 145 cells.

Essand M; Lögdahl P; Nilsson S; Wartenberg M; Acker H; Carlsson J
Article: INTERNATIONAL JOURNAL OF CANCER. 1996;67(4):573-579

Estrogen induces apoptosis in a rat prostatic adenocarcinoma: association with an increased expression of TGF-beta 1 and its type-I and type-II receptors.

Landström M; Eklöv S; Colosetti P; Nilsson S; Damber JE; Bergh A; Funa K
Article: ANTICANCER RESEARCH. 1996;16(4A):1819-1822

Estramustine-binding protein (EMBP) content in four different cell lines and its correlation to estramustine induced metaphase arrest.

Eklöv S; Mahdy E; Wester K; Björk P; Malmström PU; Busch C; Nilsson S
Article: PROSTATE. 1996;29(1):15-19

Deoxythymidine kinase in the staging of prostatic adenocarcinoma.

Letocha H; Eklöv S; Gronowitz S; Norlén BJ; Nilsson S
Article: JOURNAL OF CLINICAL PATHOLOGY. 1996;49(5):381-385

Monocyte activation in patients with non-seminomatous germ cell tumour of the testis before and after tumour eradication.

Trulson A; Nilsson S; Venge P
Article: EUROPEAN JOURNAL OF CANCER. 1996;32A(4):598-602

Mutant p53 protein as a predictor of survival in endometrial carcinoma.

Strang P; Nordstöm B; Nilsson S; Bergström R; Tribukait B
Article: ACTA RADIOLOGICA. 1996;37(2):180-185

Positron emission tomography in the diagnosis and staging of urinary bladder cancer.

Ahlström H; Malmström PU; Letocha H; Andersson J; Långström B; Nilsson S
Article: ACTA ONCOLOGICA. 1996;35(4):489-492

99mTc-dextran-antibody conjugates. Labelling procedures.

Márquez M; Westlin JE; Nilsson S; Holmberg AR
Article: ACTA ONCOLOGICA. 1996;35(4):483-488

Estramustine-binding protein (EMBP) in renal cell carcinoma immunohistochemistry, immunoscintigraphy and in vitro estramustine effects.

Edgren M; Westlin JE; Letocha H; Nordgren H; Kälkner KM; Nilsson S
Article: ACTA ONCOLOGICA. 1996;35(4):445-450

Adverse effects after radical external beam radiotherapy of localized prostatic adenocarcinoma using two-dimensional dose-planning and a limited field technique.

Ljung G; Häggman M; Hansson H; Holmberg L; Nilsson S
Article: CANCER RESEARCH. 1995;55(23 Suppl):5805s-5810s

Metastatic hormone-refractory prostatic adenocarcinoma expresses somatostatin receptors and is visualized in vivo by [111In]-labeled DTPA-D-[Phe1]-octreotide scintigraphy.

Nilsson S; Reubi JC; Kalkner KM; Laissue JA; Horisberger U; Olerud C; Westlin JE
Article: CANCER RESEARCH. 1995;55(23 Suppl):5801s-5804s

Somatostatin receptor scintigraphy in patients with carcinoid tumors: comparison between radioligand uptake and tumor markers.

Kälkner KM; Janson ET; Nilsson S; Carlsson S; Oberg K; Westlin JE
Article: CANCER RESEARCH. 1995;55(23 Suppl):5794s-5800s

Human biodistribution of [111In]diethylenetriaminepentaacetic acid-(DTPA)-D-[Phe1]-octreotide and peroperative detection of endocrine tumors.

Ohrvall U; Westlin JE; Nilsson S; Wilander E; Juhlin C; Rastad J; Akerström G
Article: CANCER RESEARCH. 1995;55(23 Suppl):5710s-5713s

Labeling of polypeptides with technetium-99m using a dextran spacer.

Holmberg A; Marquez M; Westlin JE; Nilsson S
Article: SURGERY. 1995;118(5):893-900

Scintigraphy and biodistribution of monoclonal adrenocortical antibody in mice grafted with human adrenocortical carcinoma.

Ohrvall U; Backlin K; Juhlin C; Westlin JE; Arnberg H; Bjerneroth G; Nilsson S; Akerström G; Rastad J
Article: ONCOLOGY REPORTS. 1995;2(5):863-869

The use of artificial-intelligence neural networks in the evaluation of treatment plans for external-beam radiotherapy.

Lennernas B; Isaksson U; Nilsson S
Article: ONCOLOGY REPORTS. 1995;2(5):717-721

Mao-a enzyme binding in bladder-cancer characterized with [C-11] harmine in frozen-section autoradiography.

Goller L; Bergstrom M; Nilsson S; Westerberg G; Langstrom B
Article: ONCOLOGY REPORTS. 1995;2(4):543-548

Positron emission tomography utilizing C-11 5-hydroxytryptophan, plasma biochemistry and neuroendocrine immunohistochemistry of metastatic renal-cell carcinoma.

Westlin J; Edgren M; Letocha H; Stridsberg M; Wilander E; Nilsson S
Article: ONCOLOGY REPORTS. 1995;2(4):537-541

A comparison of positron emission tomography (pet) utilizing C-11 methionine and computerized-tomography in the diagnosis of renal-cell adenocarcinoma.

Edgren M; Westlin J; Ahlstrom H; Nilsson S
Article: LUNG CANCER. 1995;12(3):183-198

Increased radioresistance of an in vitro transformed human small cell lung cancer cell line.

Brodin O; Arnberg H; Bergh J; Nilsson S
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 1995;6(4):825-831

Adrenocortical carcinoma - a clinical and immunohistochemical study.

Edgren M; Eriksson B; Wilander E; Nilsson S; Oberg K
Article: SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION. 1995;55(2):153-161

A novel IRMA and ELISA for quantifying cytokeratin 8 and 18 fragments in the sera of healthy individuals and cancer patients.

Silén A; Wiklund B; Andersson EL; Nilsson S
Article: ACTA ONCOLOGICA. 1995;34(7):959-964

Field displacement during external radiotherapy in prostatic adenocarcinoma treated with radioactive 198Au implants and external irradiation.

Lennernäs B; Letocha H; Rikner G; Magnusson A; Nilsson S
Article: ACTA ONCOLOGICA. 1995;34(7):953-958

External beam radiotherapy of localized prostatic adenocarcinoma. Evaluation of conformal therapy, field number and target margins.

Lennernäs B; Rikner G; Letocha H; Nilsson S
Article: ACTA ONCOLOGICA. 1995;34(7):945-952

Transrectal ultrasonically-guided core biopsies in the assessment of local cure of prostatic cancer after radical external beam radiotherapy.

Ljung G; Norberg M; Hansson H; de la Torre M; Egevad L; Holmberg L; Busch C; Nilsson S
Article: ANTIBODY, IMMUNOCONJUGATES, AND RADIOPHARMACEUTICALS. 1995;8(4):215-226

Positron emission tomography in the management of metastatic renal cell carcinoma

Edgren M; Westlin JE; Ahlstrom H; Letocha H; Malmstrom PU; Langstrom B; Nilsson S
Article: ANTIBODY, IMMUNOCONJUGATES, AND RADIOPHARMACEUTICALS. 1995;8(3):179-198

UPTAKE MODIFICATION OF A PROSTATE-REACTIVE MONOCLONAL-ANTIBODY IN PROSTATIC-CARCINOMA SPHEROIDS

ESSAND M; NILSSON S; CARLSSON J
Article: ANTIBODY, IMMUNOCONJUGATES, AND RADIOPHARMACEUTICALS. 1995;8(1):23-38

C-11 METHIONINE POSITRON EMISSION TOMOGRAPHY IN THE MANAGEMENT OF PROSTATIC-CARCINOMA

NILSSON S; KALKNER KM; GINMAN C; AHLSTROM H; NORLEN BJ; LETOCHA H; WESTLIN JE
Article: ANTIBODY, IMMUNOCONJUGATES, AND RADIOPHARMACEUTICALS. 1995;8(1):11-21

SOMATOSTATIN RECEPTOR SCINTIGRAPHY IN METASTATIC HORMONE-REFRACTORY PROSTATIC-CARCINOMA

KALKNER KM; GINMAN C; WESTLIN JE; LETOCHA H; NILSSON S
Article: ANTIBODY, IMMUNOCONJUGATES, AND RADIOPHARMACEUTICALS. 1995;8(3):171-177

IN-VIVO PROPERTIES OF I-125 SOMATOSTATIN-DEXTRAN CONJUGATES

HOLMBERG A; LJUNGSTEDTPAHLMAN I; MARQUEZ M; WESTLIN JE; NILSSON S
Show more

All other publications

Letter: EUROPEAN UROLOGY. 2019;75(3):e51-e52

The Case Against the European Medicines Agency's Change to the Label for Radium-223 for the Treatment of Metastatic Castration-resistant Prostate Cancer.

O'Sullivan JM; Heinrich D; James ND; Nilsson S; Ost P; Parker CC; Tombal B
Review: PROSTATE CANCER AND PROSTATIC DISEASES. 2018;21(1):37-47

Current approaches to incorporation of radium-223 in clinical practice.

Parker C; Heidenreich A; Nilsson S; Shore N
Review: SEMINARS IN NUCLEAR MEDICINE. 2016;46(6):544-556

Radium-223 Therapy of Bone Metastases in Prostate Cancer.

Nilsson S
Review: CURRENT ONCOLOGY REPORTS. 2016;18(2):14

Radionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer.

Nilsson S
Corrigendum: SPRINGERPLUS. 2016;5(1):2084

Erratum to: Identification of mutations, gene expression changes and fusion transcripts by whole transcriptome RNAseq in docetaxel resistant prostate cancer cells.

Ma Y; Miao Y; Peng Z; Sandgren J; De Ståhl TD; Huss M; Lennartsson L; Liu Y; Nistér M; Nilsson S; Li C
Review: EXPERT OPINION ON DRUG SAFETY. 2015;14(7):1127-1136

Radium-223 dichloride for the treatment of bone metastatic castration-resistant prostate cancer: an evaluation of its safety.

Nilsson S
Review: AMERICAN SOCIETY OF CLINICAL ONCOLOGY EDUCATIONAL BOOK / ASCO. AMERICAN SOCIETY OF CLINICAL ONCOLOGY. MEETING. 2014;:e132-e139

Alpha-emitter radium-223 in the management of solid tumors: current status and future directions.

Nilsson S
Editorial comment: JOURNAL OF UROLOGY. 2013;189(6):2107-2108

Re: Early salvage radiation therapy combined with short-term hormonal therapy in recurrent prostate cancer after radical prostatectomy: single-institution 4-year data on outcome, toxicity, health-related quality of life and co-morbidities from 184 consecutive patients treated with 70 Gy.

Taneja SS
Review: EUROPEAN JOURNAL OF CANCER. 2012;48(5):678-686

A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer.

Nilsson S; Strang P; Aksnes AK; Franzèn L; Olivier P; Pecking A; Staffurth J; Vasanthan S; Andersson C; Bruland ØS
Review: LAKARTIDNINGEN. 2012;109(8):412-415

[New prospects for curative radiotherapy of local advanced prostatic cancer].

Nilsson S; Castellanos E
Editorial comment: ACTA ONCOLOGICA. 2011;50 Suppl 1:90-91

Introduction: therapy with curative intent.

Nilsson S; Cohn-Cedermark G; Wiklund P
Meeting abstract: EUROPEAN UROLOGY OPEN SCIENCE. 2011;10(2):335

ALKALINE PHOSPHATASE (ALP) NORMALIZATION AT 12 WEEKS AND HEMATOLOGIC PROFILE WITH REPEATED DOSING IN PATIENTS WITH BONE METASTASES FROM CASTRATION-RESISTANT PROSTATE CANCER (CRPC) TREATED WITH RADIUM-223 (ALPHARADIN™)

Parker C; O'Bryan-Tear CG; Bolstad B; Lokna A; Garcia-Vargas J; Nilsson S
Meeting abstract: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2010;78(3):S375-S376

Clinical Experience and Radiation Safety of the First-in-Class Alpha-Pharmaceutical, Alpharadin (radium-223) in Patients with Castration-Resistant Prostate Cancer (CRPC) and Bone Metastases

Nilsson S; Parker C; Biggin C; Bruland O
Meeting abstract: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2010;78(3):S363

Clinical Results In 1004 Patients with Localized Prostate Cancer Treated with External Beam Radiotherapy, High Dose-rate 192-iridium Brachytherapy Boost, and Neo-adjuvant Hormonal Therapy

Castellanos E; Cohn-Cedermark G; Hjelm-Eriksson M; Nilsson J; Lundell M; Lundell G; Levitt S; Kalkner K; Nilsson S
Meeting abstract: EUROPEAN JOURNAL OF CANCER, SUPPLEMENT. 2009;7(2):412

Alpha-emitting Radium-223: two years follow up from a randomized phase II study in patients with bone metastases from hormone refractory prostate cancer

Nilsson S; Franzen L; Parker C; Bolstad B; Ramdahl T; Thuresson M; Bruland O
Meeting abstract: EUROPEAN JOURNAL OF CANCER, SUPPLEMENT. 2009;7(2):409

A double-blind, randomised dose-response phase II, multicentre study of radium-223 for the palliation of painful bone metastases in castration refractory prostate cancer patients

Nilsson S; Strang P; Franzen L; Olivier P; Pecking A; Staffurth J; Vasanthan S; Andersson C; Bruland OS; Aksnes AK
Review: UROLOGY. 2008;71(6):1001-1006

Testosterone surge: rationale for gonadotropin-releasing hormone blockers?

van Poppel H; Nilsson S
Meeting abstract: BONE. 2008;42:S108-S109

Zoledronic acid induces caspase dependent apoptosis in renal cancer cell lines

Ullen A; Lennartsson L; Kalkner K-M; Sandstroem P; Lennemaes B; Linder S; Nilsson S
Review: TUMOR BIOLOGY. 2008;29(5):311-322

Current status of prognostic immunohistochemical markers for urothelial bladder cancer.

Rosenblatt R; Jonmarker S; Lewensohn R; Egevad L; Sherif A; Kälkner KM; Nilsson S; Valdman A; Ullén A
Meeting abstract: EUROPEAN JOURNAL OF CANCER, SUPPLEMENT. 2007;5(4):295

Placebo-controlled, randomized, phase II study of radium-223 in metastatic hormone refractory prostate cancer (HRPC)

Nilsson S; Franzen L; Tyrrel C; Blom R; Tennvall J; Lennernas B; Johannessen DC; Sokal M; Parker C; Bruland OS
Published conference paper: CLINICAL CANCER RESEARCH. 2006;12(20 Pt 2):6250s-6257s

High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?

Bruland ØS; Nilsson S; Fisher DR; Larsen RH
Meeting abstract: RADIOTHERAPY AND ONCOLOGY. 2006;78:S23-S24

Bone-seeking radiopharmaceuticals in patients with skeletal metastases. Clinical experience using alpha-emitting radium-223

Nilsson S; Larsen RH; Bruland OS
Published conference paper: ACTA ONCOLOGICA. 2006;45(7):870-875

A prospective Phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma.

Svedman C; Sandström P; Pisa P; Blomgren H; Lax I; Kälkner K-M; Nilsson S; Wersäll P
Meeting abstract: RADIOTHERAPY AND ONCOLOGY. 2005;76:S37

Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma

Wersäll PJ; Blomgren H; Lax I; Kälkner KM; Linder C; Lundell G; Nilsson B; Nilsson S; Näslund I; Pisa P; Svedman C
Meeting abstract: RADIOTHERAPY AND ONCOLOGY. 2005;76:s112

A new implant for automatic high precision real time patient positioning in radiotherapy (RT):: A technical description of a GPS system for RT and on its initial tst on a phantom and in man

Lennernäs B; Iustin R; Albertsson P; Gustafsson T; Nilsson S; Lewitt S; Rosengren B
Published conference paper: SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, SUPPLEMENT. 2005;(216):34-63

Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens.

Epstein JI; Amin M; Boccon-Gibod L; Egevad L; Humphrey PA; Mikuz G; Newling D; Nilsson S; Sakr W; Srigley JR; Wheeler TM; Montironi R
Published conference paper: SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, SUPPLEMENT. 2005;(216):20-33

Prognostic and predictive factors and reporting of prostate carcinoma in prostate needle biopsy specimens.

Amin M; Boccon-Gibod L; Egevad L; Epstein JI; Humphrey PA; Mikuz G; Newling D; Nilsson S; Sakr W; Srigley JR; Wheeler TM; Montironi R
Published conference paper: SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, SUPPLEMENT. 2005;(216):8-19

Prognostic and predictive factors in prostate cancer: historical perspectives and recent international consensus initiatives.

Srigley JR; Amin M; Boccon-Gibod L; Egevad L; Epstein JI; Humphrey PA; Mikuz G; Newling D; Nilsson S; Sakr W; Wheeler TM; Montironi R
Published conference paper: ANNALS OF THE NEW YORK ACADEMY OF SCIENCES. 2004;1028:361-374

Phase I trial on sms-D70 somatostatin analogue in advanced prostate and renal cell cancer.

Joensuu TK; Nilsson S; Holmberg AR; Márquez M; Tenhunen M; Saarto T; Joensuu H
Review: ACTA ONCOLOGICA. 2004;43(4):316-381

A systematic overview of radiation therapy effects in prostate cancer.

Nilsson S; Norlén BJ; Widmark A
Review: SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY. 2003;37(1):10-15

Postoperative radiotherapy after prostatectomy--a review.

Lennernäs B; Edgren M; Häggman M; Norlén BJ; Nilsson S
Published conference paper: CANCER. 2002;94(4 Suppl):1293-1297

A novel somatostatin conjugate with a high affinity to all five somatostatin receptor subtypes.

Wulbrand U; Feldman M; Pfestroff A; Fehman H-C; Du J; Hiltunen J; Marquez M; Arnold R; Westlin J-E; Nilsson S; Holmberg AR
Review: ACTA ONCOLOGICA. 2001;40(2-3):371-390

A systematic overview of chemotherapy effects in urothelial bladder cancer.

Nilsson S; Ragnhammar P; Glimelius B; Nygren P; SBU-group. Swedish Council of Technology Assessmen
Published conference paper: SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, SUPPLEMENT. 2000;(205):136-165

Precancerous lesions in the kidney.

Van Poppel H; Nilsson S; Algaba F; Bergerheim U; Dal Cin P; Fleming S; Hellsten S; Kirkali Z; Klotz L; Lindblad P; Ljungberg B; Mulders P; Roskams T; Ross RK; Walker C; Wersäll P
Published conference paper: CLINICAL CANCER RESEARCH. 1999;5(10 Suppl):3056s-3058s

Ion exchange tumor targeting: a new approach.

Holmberg AR; Wilchek M; Márquez M; Westlin JE; Du J; Nilsson S
Published conference paper: ACTA ONCOLOGICA. 1999;38(3):373-377

Treatment with high dose [(111)In-DTPA-D-PHE1]-octreotide in patients with neuroendocrine tumors--evaluation of therapeutic and toxic effects.

Tiensuu Janson E; Eriksson B; Oberg K; Skogseid B; Ohrvall U; Nilsson S; Westlin JE
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 1998;100(3):608-609

Eosinophils and serum eosinophilic cationic proteins in interleukin-2-based immunotherapy for cancer

Trulson A; Nilsson S; Venge P
Published conference paper: CANCER. 1997;80(12 Suppl):2743-2748

Objective responses after fractionated infusional brachytherapy of unresectable pancreatic adenocarcinomas.

Westlin JE; Andersson-Forsman C; Garske U; Linné T; Aas M; Glimelius B; Lindgren PG; Order SE; Nilsson S
Published conference paper: CANCER. 1997;80(12 Suppl):2495-2500

A gamma detector probe with ex vivo detection of carcinoid tumors superior to intraoperative palpation.

Ohrvall U; Westlin JE; Kjellberg F; Nilsson S; Juhlin C; Rastad J; Akerström G; Lundqvist H
Published conference paper: CANCER. 1997;80(12 Suppl):2490-2494

Intraoperative gamma detection reveals abdominal endocrine tumors more efficiently than somatostatin receptor scintigraphy.

Ohrvall U; Westlin JE; Nilsson S; Juhlin C; Rastad J; Lundqvist H; Akerström G
Published conference paper: CANCER. 1997;80(12 Suppl):2398-2403

Radioimmunoscintigraphy with a novel monoclonal antiprostate antibody (E4): an experimental study in nude mice.

Rydh A; Riklund Ahlström K; Widmark A; Johansson L; Nilsson S; Bergh A; Damber JE; Stigbrand T; Hietala SO
Published conference paper: CANCER. 1997;80(12 Suppl):2385-2389

The potential of radiolabeled EGF-dextran conjugates in the treatment of urinary bladder carcinoma.

Bue P; Márquez M; Malmström PU; Westlin JE; Nilsson S; Holmberg AR
Letter: RADIOTHERAPY AND ONCOLOGY. 1995;37(3):249-250

A new patient positioning system using magnetic implants and magnetic field sensors.

Lennernäs B; Nilsson S
Other: PAIN. 1995;60(1):111-114

Rapid, reproducible pain relief with [131I]iodine-meta-iodobenzylguanidine in a boy with disseminated neuroblastoma.

Westlin J-E; Letocha H; Jakobson Å; Strang P; Martinsson U; Nilsson S
Show more

Articles

All other publications

News from KI

Events from KI